Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Nanomedicine (Lond). 2008 Dec;3(6):761–776. doi: 10.2217/17435889.3.6.761

Figure 8. Cytotoxicity of different formulations in human multidrug-resistant ovarian (A2780/AD) and breast (MCF-7/AD) cancer cells.

Figure 8

The cells were incubated for 48 h with the indicated formulations. The concentration of siRNA and composition of cationic liposomes in all formulations were the same. Means ± standard deviation are shown. 1: Free DOX; 2: Cationic liposomes–DOX; 3: Cationic liposomes–BCL2 siRNA; 4: Cationic liposomes–DOX–MDR1 siRNA; 5: Cationic liposomes-MDR1 siRNA–BCL2 siRNA + Free DOX; 6: Cationic liposomes–DOX–MDR1 siRNA–BCL2 siRNA.

*p <0.05 when compared with free DOX.